Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

COPENHAGEN, Denmark - Genmab A/S (NASDAQ:GMAB), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $12.2 billion and an impressive 95% gross profit ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...

Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook ...

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on ...

In a report released today, Yaron Werber from TD Cowen maintained a Hold rating on Genmab (GMAB – Research Report). The company’s shares closed ...

Truist Securities reiterated their Buy rating on Genmab A/S (NASDAQ:GMAB) with a steady price target of $50.00. The firm's analysts remain confident in the biotech company's prospects, particularly in ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...

Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, ...

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.